NCT07297225Completed
Metabolic Dysfunction-Associated Fatty Liver Disease Impairs Intraoperative Indocyanine Green Fluorescence Cholangiography Quality: Development and Validation of a Predictive Model
Source: ClinicalTrials.gov · Last updated 22 Dec 2025
Brief summary (registry, in English)
Near-infrared fluorescence cholangiography has been shown to improve the clinical outcomes of laparoscopic cholecystectomy (LC). However, it remains unclear whether hepatic steatosis in patients with metabolic dysfunction-associated fatty liver disease (MAFLD) influences the quality of indocyanine green fluorescence imaging (ICG-FI), and whether the quality can be predicted preoperatively. This study aimed to evaluate the impact of MAFLD on intraoperative fluorescence quality and to develop a multiple linear regression model for predicting intraoperative ICG-FI.
- Status (registry)
- Completed
- Study type
- Observational
- Enrollment
- 150 (actual)
- First submitted
- 21 Sept 2025
- Start date
- 31 Jan 2025
- Primary completion date
- 30 May 2025
- Lead sponsor
- Zhujiang Hospital
- Diseases
- Fatty liver disease (MASLD/MASH)
- NCT number
- NCT07297225
What you commit to
- Study type: Observational
- Participants enrolled: 150
- From 31 Jan 2025 to the primary completion date, 30 May 2025
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Use of medications affecting biliary excretion within 2 weeks prior to surgery; (3) LC without ICG-FI;
- (4) Incomplete clinical data.
Other illness
- Known allergy to ICG or iodinated contrast agents;
Who the study is looking for
- Age 18-75 years, any sex;
- Definite surgical indication for cholecystectomy;
- Underwent LC;
- No severe contraindications such as significant cardiac, pulmonary, renal, or cerebral dysfunction.
Age in the registry: 18 years to 75 years · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Zhujiang Hospital of Southern Medical University Coordinator of this site? Confirm its status | Guangzhou | China | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.